Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Vor Biopharma	Nurix Therapeutics	PureTech Health	Silverback Therapeutics	4D Molecular Therapeutics
Symbol	NYSE:VOR	NASDAQ:NRIX	LON:PRTC	NASDAQ:SBTX	NASDAQ:FDMT
Price Information
Current Price	$19.51	$25.89	GBX 360.50	$26.40	$26.33
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.5	2.0	1.5	1.7	1.3
Analysis Score	4.3	3.5	3.5	3.5	3.3
Community Score	3.2	4.1	3.8	4.4	3.3
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.0	0.0	0.0
Earnings & Valuation Score	0.0	0.6	0.0	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$48.20	$46.00	GBX 496.25	$50.25	$45.50
% Upside from Price Target	147.05% upside	77.67% upside	37.66% upside	90.34% upside	72.81% upside
Trade Information
Market Cap	$731.50 million	$1.12 billion	£1.03 billion	$862.45 million	$705.26 million
Beta	N/A	N/A	N/A	N/A	N/A
Average Volume	232,808	459,851	236,715	214,772	150,651
Sales & Book Value
Annual Revenue	N/A	N/A	£11.77 million	N/A	N/A
Price / Sales	N/A	N/A	87.58	N/A	N/A
Cashflow	N/A	N/A	GBX 138.04 per share	N/A	N/A
Price / Cash	N/A	N/A	2.61	N/A	N/A
Book Value	N/A	N/A	GBX 234.30 per share	N/A	N/A
Price / Book	N/A	N/A	0.02	N/A	N/A
Profitability
Net Income	N/A	N/A	N/A	N/A	N/A
EPS	N/A	N/A	GBX 1.40	N/A	N/A
Trailing P/E Ratio	0.00	0.00	257.50	0.00	0.00
Forward P/E Ratio	∞	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	N/A	N/A	N/A	N/A	N/A
Return on Assets (ROA)	N/A	N/A	N/A	N/A	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	11.72%	N/A	N/A
Current Ratio	N/A	N/A	2.29%	N/A	N/A
Quick Ratio	N/A	N/A	2.25%	N/A	N/A
Ownership Information
Institutional Ownership Percentage	N/A	81.99%	N/A	N/A	N/A
Insider Ownership Percentage	N/A	N/A	N/A	N/A	N/A
Miscellaneous
Employees	88	135	300	54	83
Shares Outstanding	37.13 million	44.35 million	285.90 million	34.90 million	26.69 million
Next Earnings Date	8/5/2021 (Estimated)	N/A	N/A	8/12/2021 (Estimated)	8/12/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results americanbankingnews.com - May 14 at 11:50 AM
	4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights finance.yahoo.com - May 14 at 12:04 AM
	4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 ... apnews.com - May 13 at 7:22 AM
	4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME finance.yahoo.com - May 12 at 9:11 PM
	4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insiders Increased Their Holdings finance.yahoo.com - May 10 at 4:00 PM
	4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform finance.yahoo.com - May 4 at 8:20 PM
	4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference finance.yahoo.com - April 30 at 9:29 AM
	4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies finance.yahoo.com - April 27 at 5:52 PM
	Is FDMT Stock A Buy or Sell? finance.yahoo.com - April 26 at 3:08 PM
	What Kind Of Shareholders Hold The Majority In 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) Shares? nasdaq.com - April 17 at 5:27 PM
	4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights finance.yahoo.com - March 25 at 6:10 PM
	We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth finance.yahoo.com - March 11 at 8:12 AM
	Genetic Modification Therapies Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030 marketwatch.com - March 11 at 1:08 AM
	4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 ... apnews.com - March 9 at 9:09 AM
	4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease finance.yahoo.com - March 9 at 9:09 AM
	4D Molecular Therapeutics, Inc. Common Stock (FDMT) nasdaq.com - January 31 at 12:42 AM
	4D Molecular Therapeutics Inc money.usnews.com - December 16 at 11:40 PM
	BioAtla Is the Latest Biotech IPO to Pop finance.yahoo.com - December 16 at 6:39 PM
	4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of ... apnews.com - December 16 at 8:39 AM

Date	Company	Brokerage	Action
5/7/2021	Vor Biopharma	B. Riley	Reiterated Rating
3/9/2021	Vor Biopharma	Barclays	Initiated Coverage
3/8/2021	Vor Biopharma	The Goldman Sachs Group	Initiated Coverage
3/8/2021	Vor Biopharma	Stifel Nicolaus	Initiated Coverage
3/8/2021	Vor Biopharma	Evercore ISI	Initiated Coverage
5/6/2021	Nurix Therapeutics	Royal Bank of Canada	Initiated Coverage
4/20/2021	Nurix Therapeutics	Berenberg Bank	Initiated Coverage
2/17/2021	Nurix Therapeutics	Needham & Company LLC	Reiterated Rating
2/17/2021	Nurix Therapeutics	Piper Sandler	Boost Price Target
1/29/2021	Nurix Therapeutics	JPMorgan Chase & Co.	Boost Price Target
11/18/2020	Nurix Therapeutics	Robert W. Baird	Initiated Coverage
4/15/2021	PureTech Health	Liberum Capital	Reiterated Rating
1/19/2021	PureTech Health	Jefferies Financial Group	Reiterated Rating
7/8/2020	PureTech Health	Peel Hunt	Reiterated Rating
6/2/2020	PureTech Health	Peel Hunt	Reiterated Rating
4/13/2021	Silverback Therapeutics	SVB Leerink	Boost Price Target
12/29/2020	Silverback Therapeutics	HC Wainwright	Initiated Coverage
1/5/2021	4D Molecular Therapeutics	Bank of America	Initiated Coverage

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources